Abstract Background Capecitabine (Xeloda®) is a cytotoxic, antimetabolite chemotherapeutic agent. Its most common adverse events are diarrhea, hand-foot syndrome (HFS), hyperbilirubinemia, hyperpigmentation, fatigue, abdominal pain, and other gastrointestinal effects. HFS or palmar-plantar erythrodysesthesia (PPE) is an adverse reaction resulting from therapy with chemotherapeutic agents, classified into three degrees. Hyperpigmentation, as an adverse effect of capecitabine, can occur in different locations and with different patterns. The skin, nails and oral mucosal membrane can be affected. Objective The objective of this study was to report and discuss oral hyperpigmentation associated with HFS caused by the use of capecitabine, which is still poorly described in the literature. Methodology A literature review was carried out using the online databases PubMed, Scielo, BVS, Lilacs, Medline, BBO and Google Scholar, associating the descriptors “Capecitabine”, “Pigmentation Disorders”, “Oral mucosa”, “Cancer” and “Hand-Foot Syndrome”, which were related and used to exemplify, discuss and report the exposed clinical case. Results This case report corroborates the literature regarding the incidence in females and black skin persons like this patient who was affected by HFS when undergoing antineoplastic therapy with capecitabine and presented hyperpigmentation of the hands, feet and oral mucosa. On the oral mucosa, the hyperpigmented spots were diffuse, showing a blackish color and irregular edges. Their pathophysiology remains unknown. Study limitations Few articles citing capecitabine-associated pigmentation. Conclusions It is hoped that this study may contribute to the identification and correct diagnosis of hyperpigmentation in the oral cavity, as well as call attention to the adverse effects related to capecitabine.

RESUMO O atendimento odontológico hospitalar é uma estratégia educativa e assistencial que tem como objetivo intervir, de forma multidisciplinar, no processo saúde-doença de indivíduos vulneráveis, uma vez que a saúde bucal insatisfatória é um fator de risco para infecções locais e sistêmicas. Pacientes em tratamento oncológico geralmente apresentam manifestações orais por causa das terapias antineoplásicas às quais são submetidos. Quimioterapia, radioterapia e cirurgia oncológica, quando realizadas na região da cabeça e pescoço, têm o potencial de gerar efeitos colaterais na cavidade bucal. Essas manifestações orais podem ser graves e interferir nos resultados da terapia medicamentosa, levando a importantes complicações sistêmicas, que podem aumentar a permanência hospitalar, os custos do tratamento e afetar a qualidade de vida. Diante dessa realidade, a incorporação do cirurgião-dentista na equipe multiprofissional em oncologia é fundamental para garantir a integralidade do cuidado em todas as etapas da terapia. Este artigo se propõe a relatar uma série de casos de pacientes atendidos no Serviço de Odontologia do Centro de Oncologia do Hospital Universitário Oswaldo Cruz da Universidade de Pernambuco, que exemplificam possibilidades de atuação do cirurgião-dentista em ambiente hospitalar, participando como membro ativo de uma equipe multidisciplinar em oncologia.

ABTRACT Hospital dental care is an educational and health care strategy whose purpose is to intervene, in a multidisciplinary way, in the health-disease process of vulnerable individuals, as unsatisfactory oral health is a risk factor for local and systemic infections. Patients in cancer treatment usually present oral manifestations because of the antineoplastic therapies to which they are submitted. Chemotherapy, radiation and cancer surgery, when the latter held in the head and neck region, have the potential to generate side effects in the oral cavity. These oral manifestations can be serious and interfere with the results of medical therapy, leading to important systemic complications, which can increase hospital stay, treatment costs, and affect the quality of life. In view of this reality, the incorporation of the dentist into the multiprofessional team in oncology is essential to guarantee the patient’s integral care in all stages of therapy. This article then proposes to report a series of cases of patients attended at the Dentistry Service of the Oncology Center of the Oswaldo Cruz University Hospital of the University of Pernambuco, that exemplify the dental surgeon performance in a hospital environment, participating as an active member of a multidisciplinary team in oncology.

Os autores buscaram verificar, neste estudo, a presença do papilomavírus humano (HPV) de baixo e de alto risco em carcinomas orais através do teste de captura híbrida Digene® (São Paulo-SP, Brasil) em amostras colhidas pela citologia esfoliativa bucal e, ainda, avaliar comparativamente as referidas leituras com alterações celulares indicativas deste vírus obtidas com a interpretação citológica óptica convencional (hematoxilina-eosina (HE)/Papanicolaou). Quarenta indivíduos concordaram, espontaneamente, através de assinatura do termo de consentimento livre e esclarecido, em participar da pesquisa, e seus dados clínicos foram analisados. Entre as 40 amostras provenientes da citologia esfoliativa 29 (72,5%) mostraram-se negativas para presença de HPV-DNA de baixo e de alto risco; nove (22,5%) foram positivas para o HPV-DNA de baixo e de alto risco; uma (2,5%) foi positiva apenas para o HPV de baixo risco; e também uma (2,5%) foi positiva apenas para o HPV de alto risco. Houve concordância entre todos os resultados positivos para presença de HPV-DNA nas amostras citológicas submetidas ao teste de captura híbrida Digene® e na leitura de esfregaço citológico ao microscópio óptico convencional. Desta forma, conclui-se que o vírus HPV pode comportar-se como mais um co-carcinógeno para o câncer de boca, à semelhança do carcinoma uterino.

The authors set out in this study to verify the presence of low- and high-risk DNA of human papillomavirus (HPV) in oral cancer by means of the hybrid capture Digene® test (São Paulo-SP, Brazil) in smears from exfoliative cytology and also to compare the findings with those of conventional light microscopy (hematoxylin-eosin (HE)/Papanicolaou). Forty individuals gave their written informed consent to participate in the study and also had their clinical data analyzed. The 40 exfoliative cytology examinations performed to date produced the following results: 29 (72.5%) negative for low- and high-risk HPV-DNA; nine (22.5%) positive for low- and high-risk HPV-DNA; one (2.5%) positive for low-risk HPV-DNA; and one (2.5%) positive for high-risk HPV-DNA. There was agreement among the findings for the presence of DNA-HPV for both exfoliative cytology (smear to hybrid capture Digene® test and the cytological smear readings made by conventional light microscopy). It was therefore concluded that the HPV virus may be a cocarcinogen of the mouth cancer as it is in the cervix cancer.